Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
3.9
Journals
Biomedicines
Special Issues
Endocrine Disorders: From Pathophysiology to Novel Therapeutic Approaches
share announcement

Endocrine Disorders: From Pathophysiology to Novel Therapeutic Approaches

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Endocrinology and Metabolism Research".

Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 472

Special Issue Editor

Dr. Esther Osher

E-Mail Website
Guest Editor
Institute of Endocrinology, Metabolism, and Hypertension, Tel Aviv-Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Israel
Interests: neuroendocrine tumors; metabolic impairment and diabetes; immune checkpoint; endocrinopathies

Special Issue Information

Dear Colleagues,

Endocrine disorders result from dysfunction of the endocrine system. The endocrine system includes the glands that secrete hormones, the receptors that respond to hormones, and the organs directly affected by hormones. Dysfunction may occur at any point and affect the body's metabolic process, growth and development, reproductive aging, and many other physiological activities. Endocrine disorders are complex chronic diseases. More and more people are suffering from them. However, the current therapeutic options and effects are all limited and often accompanied by adverse reactions.

This Special Issue will cover all research on the molecular mechanisms of the pathophysiology of all endocrine disorders, cellular and animal disease models, new drugs, and cell and gene therapy options.

Dr. Esther Osher
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endocrine disorders
  • diabetes , metabolic syndrome
  • hypothyroidism
  • polycystic ovary syndrome
  • acne

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

9 pages, 247 KiB  
Article
Deficient or Normal Growth Hormone Secretion in Polish Children with Short Stature: Searching for Clinical Differences
by Katarzyna Anna Majewska, Magdalena Tchorzewska-Skrobich, Paulina Wais, Dominik Majewski, Monika Naskręcka and Andrzej Kędzia
Biomedicines 2024, 12(8), 1673; https://doi.org/10.3390/biomedicines12081673 - 26 Jul 2024
Abstract
Short stature affects approximately 2.5% of children. Some of them, when diagnosed with growth hormone deficiency (GHD), benefit from recombinant human growth hormone (rhGH) therapy; in others, this treatment is controversial. We aimed to present the clinical characteristics of Polish short stature children [...] Read more.
Short stature affects approximately 2.5% of children. Some of them, when diagnosed with growth hormone deficiency (GHD), benefit from recombinant human growth hormone (rhGH) therapy; in others, this treatment is controversial. We aimed to present the clinical characteristics of Polish short stature children in the context of current GHD diagnostic standards, as obtaining more data gives a broader foundation for the potential modifications of diagnostic and therapeutic recommendations. This retrospective analysis was based on a cohort of 277 short stature children divided into two subgroups depending on their peak growth hormone (GH) cutoff level, set at 10 ng/mL: 138 had growth hormone deficiency (GHD) and 137 had normal growth hormone secretion (GHN). These subgroups were then compared based on the extracted clinical data. In the obtained result, no significant differences between the GHD and GHN subgroups were found in any of the variables, including the following: gender distribution, birth weight, bone age delay, height SDS, IGF-1 SDS, vitamin D levels, celiac disease indices, prevalence of hypothyroidism or anemia. As our results point to major clinical similarities between the GHD and GHN children, it seems that distinguishing patients with normal GH secretion from those with deficient GH secretion based on a 10 ng/mL cutoff value might not be clinically relevant. Full article
(This article belongs to the Special Issue Endocrine Disorders: From Pathophysiology to Novel Therapeutic Approaches)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop